IRulya Therapeutics to Participate in the Craig-Hallum Biotech Catalyst Conference
Globe Newswire•15/10/2026•08:00 ET
0
Key Highlights
- ➤IRulya management to participate in Craig-Hallum Biotech Catalyst Conference Fireside Chat October 22, 2026
- ➤LAM-001 Phase 2b study in PH-ILD is ongoing
- ➤LAM-001 Phase 2 SAPH study anticipated to begin fourth quarter 2026
- ➤IRulya says anticipated cash runway funds operations through end of 2028
NEW HAVEN, Conn., Oct. 15, 2026 (GLOBE NEWSWIRE) -- IRulya Therapeutics Inc. (Nasdaq: IRLA), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapeutics for serious underserved diseases, today announced that senior management will participate in a Fireside Chat at the Craig-Hallum Biotech Catalyst Conference on Thursday, October 22, 2026.
Following the event, a replay will be accessible by visiting the “Events” section on the “Investors” page of IRulya’s website at www.irulya.com. A replay of the webcast will be available following the presentation and will be archived for at least 30 days.
Get started
Create a free account to read the full story.